Stocks and InvestingStocks and Investing
Thu, April 8, 2021
Wed, April 7, 2021
Tue, April 6, 2021
Mon, April 5, 2021
Sun, April 4, 2021
Thu, April 1, 2021

Robyn Karnauskas Maintained (BTAI) at Strong Buy with Decreased Target to $127 on, Apr 1st, 2021


Published on 2024-10-27 16:06:05 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $150 to $127 on, Apr 1st, 2021.

Robyn has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Robyn's Rating of Hold.



This is the rating of the analyst that currently disagrees with Robyn


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021